---
document_datetime: 2024-02-23 16:11:41
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aripiprazole-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: aripiprazole-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.891769
conversion_datetime: 2025-12-26 13:27:17.604805
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## [PLEASE SELECT THE 'Add-Ins' TAB IN THE ABOVE TOOLBAR AND CLICK THE 'FINALISE BI TEMPLATE' MACRO ICON]

h-3899-steps after\\_en

## Aripiprazole Zentiva

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| Application   | Scope   | Opinion/                   | Commission Decision   | Product Information   | Summary   |
|---------------|---------|----------------------------|-----------------------|-----------------------|-----------|
| number        |         | Notification Notifications | Issued A              | affected SmP          |           |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.e.2.z - Change in the specification parameters   |            |     | PL   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| IA/0017 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/10/2022 | n/a |      |

<div style=\"page-break-after: always\"></div>

|           | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                            |            |            |                                  |                                                                                                                                                                                                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0016   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                        | 10/08/2022 | 24/07/2023 | SmPC, Annex II, Labelling and PL | Section 4.8 of the SmPC has been updated to add 'blood prolactine decreased' in the tabulated list of all adverse reactions in line with the text of reference product. The PL has been updated accordingly. |
| IB/0015   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                        | 10/02/2021 | 04/06/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                              |
| IB/0014/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF | 23/07/2020 | n/a        |                                  |                                                                                                                                                                                                              |
| IB/0013   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO                                                                                   | 04/06/2020 | 04/06/2021 | SmPC and PL                      |                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | new additional data is required to be submitted by the MAH                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0012  | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 26/03/2020 | 02/06/2020 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Aripiprazole Zentiva in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0011 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 05/06/2019 | 02/06/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                    |
| IG/1029 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                             | 18/12/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                    |
| IB/0009 | B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation                                                                                                                                                                     | 14/03/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                    |
| IB/0008 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 06/02/2018 | 21/03/2018 | SmPC and PL            |                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                          | 08/12/2017   | n/a        |                       | IA/0007                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------|
| IB/0006   | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                 | 30/10/2017   | n/a        |                       |                         |
| IB/0005   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by         | 18/04/2017   | 21/03/2018 | Annex II              | the MAH                 |
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 09/12/2016   | 13/02/2017 | SmPC and Labelling    |                         |
| IB/0003   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 01/07/2016   | 13/02/2017 | SmPC and PL           |                         |
| IB/0002/G | This was an application for a group of variations. SPC, Labelling or PL of a                                                                                                                                                                                 | 17/03/2016   | 13/02/2017 | SmPC, Annex II and PL | C.I.2.a - Change in the |

<div style=\"page-break-after: always\"></div>

|         | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0001 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                          | 24/02/2016 | n/a |